MYGN (Myriad Genetics Inc)
Insider Trading Activity
Every open-market purchase and sale reported by MYGN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-23 | Daniel Skovronsky | Director | — | — | — |
| 2026-06-12 | Brian J Donnelly | Chief Commerical Officer | A | — | — |
| 2026-06-12 | Samraat S. Raha | President and CEO | A | — | — |
| 2026-06-09 | Rashmi Kumar | Director | Sell | — | — |
| 2026-06-05 | Paul Bisaro | Director | A | — | — |
| 2026-06-05 | Colleen F Reitan | Director | A | — | — |
| 2026-06-05 | S. Louise Phanstiel | Director | A | — | — |
| 2026-06-05 | Rashmi Kumar | Director | A | — | — |
| 2026-06-05 | Mark Steven Davis | Director | A | — | — |
| 2026-06-05 | Heinrich Dreismann | Director | A | — | — |
| 2026-06-05 | Lee Nisley Newcomer | Director | A | — | — |
| 2026-06-05 | Daniel Skovronsky | Director | A | — | — |
| 2026-06-02 | Raj Jampa | Chief Technology Officer | A | — | — |
| 2026-05-14 | Paul Bisaro | Director | Buy | — | — |
| 2026-05-04 | Brian J Donnelly | Chief Commerical Officer | F | — | — |
| 2026-04-15 | Dale Muzzey | Chief Scientific Officer | F | — | — |
| 2026-04-15 | Mark Verratti | Chief Operating Officer | F | — | — |
| 2026-03-23 | Benjamin Richard Wheeler | Chief Financial Officer | F | — | — |
| 2026-03-23 | Mark Verratti | Chief Operating Officer | F | — | — |
| 2026-03-23 | Dale Muzzey | Chief Scientific Officer | F | — | — |
| 2026-03-16 | Jennifer Lynne Fox | Chief Legal Officer | MIXED | — | — |
| 2026-03-16 | Samraat S. Raha | President and CEO | MIXED | — | — |
| 2026-03-16 | Shereen Solaiman | Chief People Officer | MIXED | — | — |
| 2026-03-16 | Benjamin Richard Wheeler | Chief Financial Officer | MIXED | — | — |
| 2026-03-16 | Mark Verratti | Chief Operating Officer | MIXED | — | — |
| 2026-03-16 | Kevin Richard Haas | Chief Technology Officer | F | — | — |
| 2026-03-16 | Dale Muzzey | Chief Scientific Officer | MIXED | — | — |
| 2026-03-16 | Brian J Donnelly | Chief Commerical Officer | A | — | — |
| 2026-03-09 | Samraat S. Raha | President and CEO | Buy | — | — |
| 2026-03-02 | Shereen Solaiman | Chief People Officer | F | — | — |
| 2026-02-27 | S. Louise Phanstiel | Director | Buy | — | — |
| 2026-02-03 | Dale Muzzey | Chief Scientific Officer | A | — | — |
| 2026-02-03 | Kevin Richard Haas | Chief Technology Officer | A | — | — |
| 2026-02-03 | Mark Verratti | Chief Operating Officer | A | — | — |
| 2026-02-03 | Benjamin Richard Wheeler | Chief Financial Officer | A | — | — |
| 2026-01-02 | Dale Muzzey | Chief Scientific Officer | F | — | — |
| 2025-12-29 | Benjamin Richard Wheeler | Chief Financial Officer | F | — | — |
| 2025-12-12 | Samraat S. Raha | President and CEO | F | — | — |
| 2025-11-04 | Margaret Ancona | EVP, Strategy & Transformation | — | — | — |
| 2025-10-24 | Natalie Munk | Chief Accounting Officer | — | — | — |
| 2025-09-22 | Benjamin Richard Wheeler | Chief Financial Officer | F | — | — |
| 2025-09-22 | Natalie Munk | Chief Accounting Officer | F | — | — |
| 2025-09-22 | Margaret Ancona | EVP, Strategy & Transformation | F | — | — |
| 2025-09-22 | Mark Verratti | Chief Operating Officer | F | — | — |
| 2025-09-04 | Jennifer Lynne Fox | Chief Legal Officer | F | — | — |
| 2025-08-19 | Benjamin Richard Wheeler | Chief Financial Officer | A | — | — |
| 2025-08-18 | Scott J. Leffler | Chief Financial Officer | — | — | — |
| 2025-06-06 | Paul Bisaro | Director | A | — | — |
| 2025-06-06 | Daniel Skovronsky | Director | A | — | — |
| 2025-06-06 | Heinrich Dreismann | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | President and CEO | 1,068,083 | — |
| — | President and CEO | 891,844 | — |
| — | Chief Scientific Officer | 697,061 | — |
| — | Chief Operating Officer | 629,646 | — |
| — | Chief Commerical Officer | 573,363 | — |
| — | President & C.E.O. | 522,216 | — |
| — | Director | 374,771 | — |
| — | Chief Scientific Officer | 326,310 | — |
| — | Chief Legal Officer | 310,362 | — |
| — | Chief Financial Officer | 298,509 | — |
| — | Chief Financial Officer | 291,812 | — |
| — | Chief People Officer | 273,585 | — |
| — | See Remarks | 264,324 | — |
| — | Chief Technology Officer | 251,889 | — |
| — | Pres. Myriad Pharmaceuticals | 234,071 | — |
| — | Director | 231,145 | — |
| — | Chief Operating Officer | 223,993 | — |
| — | Chief Financial Officer | 218,393 | — |
| — | Director | 195,507 | — |
| — | Director | 191,842 | — |
| — | Chief Technology Officer | 191,759 | — |
| — | See Remarks | 172,562 | — |
| — | Director | 171,889 | — |
| — | Chief Operating Officer | 169,040 | — |
| — | President Crescendo BioScience | 165,594 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MYGN quote page; the site-wide leaderboard is on the insider transactions hub.